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Introduction
Carbonyldiimidazole (CDI), is a commonly used reagent for the activation of carboxylic acid groups and has been used for the preparation of affinity columns (1) (2) (3) (4) (5) , the attachment of t-BOC amino acids to solid supports (6, 7) , and in the prepara tion of fatty acyl CoA thioesters (8) , phospholipids (9) (10) (11) (12) (13) (14) (15) (16) , and simple peptides (17) (18) (19) (20) (21) . In general, the activation reaction consists of reacting the carboxylic acid with an excess of CDI in an anhydrous solvent such as tetrahydrofuran, chloroform, ben zene, or dimethylformamide and the resulting activated acid is used as the acylating reagent without further purification.
We have adopted this method of activation for the preparation of esters of coenzyme A, phospholipids, and polar derivatives of hydrophobic proteins (23) . However, in each case the reaction was variable and the yield of the desired products was often low. High performance liquid chromatographic (hplc) analysis of the acylation reaction, using DNP-prolylserinamide as a model compound, indicated that this was related to the presence of CDI during the acylation reaction.
Activation of the acid by one equivalent or only a slight excess of CDI results in a slow and incomplete reaction, leaving a residual amount of free CDI unless very long activation times are used. Activation by a substantial excess of CDI results in faster and complete activation but the excess CDI is still present. The activated acyl imidazolide is normally used directly without purification due to its sensitivity to hydrolysis, and thus the excess of CDI still present reacts with the target groups and thereby prevents their acylation.
We have developed a method of complete activation of the carboxylic acid by a substantial excess of CDI, which is subse quently removed selectively by incubation of the activation mixture with Sephadex LH-20 in dry benzene. The described activation procedure completely eliminates the side reaction 1 Author to whom correspondence may be addressed.
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with the activating agent and affords the desired acylation in excellent yield.
Experimental

General
Trimesic acid ( 1,3 ,5-benzenetricarboxylic acid), l, 1-carbonyldi imidazole (CDI), and ninhydrin were purchased from Sigma Chemical Co. Sephadex LH-20 was purchased from Pharmacia and triethylamine from Pierce.
Reagent grade dimethylformamide (DMF) was dried by the addition of 0.1 volume of dry benzene, removal of 0.2 volume under reduced pressure, and storage over 4 A molecular sieve and under nitrogen. All distillation was performed under nitrogen. Benzene was dried by refluxing for 4 h over calcium hydride, distilled, and stored over 4 A molecular sieve under nitrogen. Triethylamine was distilled from ninhydrin and stored over 4 A molecular sieve, under nitrogen and at 4°C in the dark.
Synthesis of DNP-prolylserinamide
DNP-proline was activated by the addition of 1.1 equivalents of CDI in dry THF as a 60 mM solution and incubated at room temperature for l h under nitrogen. To the reactive imidazolide derivative, 3 equiva lents of the hydrochloride salt of serinamide were added as a freshly prepared 1.54 M aqueous solution in the presence of l equivalent of Bu4NOH. After 12 h at room temperature, the reaction was diluted with a 0.5 volume of water and the DNP-peptide extracted into ethyl acetate.
The peptide product was purified by preparative hplc on a reversed phaseµ Bondapak C 18 column, which was equilibrated and run isocra tically with 1 % aqueous acetic acid containing 10% methanol. The DNP-peptide was dried several times from anhydrous pyridine and then stored as a 25 mM solution in dry pyridine over molecular sieve and under nitrogen. 
Preparation of acid imidazolides
The DT-TM acid (I M in dry DMF) was transferred to a flamed and analyzing a portion using a 4.6 x 250 mm µBondapak C18 column equilibrated with 35% methanol in 10 mM sodium acetate, pH 4.4. The column was developed at 1 mL/min, while the methanol content of the eluent was increased to 100% over 15 min to afford a 10-min separation between the retention times of the starting peptide and the trimesylated product.
Results and discussion
Carbonyldiimidazole (CDI) has been used extensively (22) for the activation of carbox ylic acid groups since it reacts quanti tatively to produce the acid imidazolide. An excess of CDI is used to ensure complete activation of the acid since the purity of the commercially available CDI is variable due to its extreme sensitivity to water, and since any residual water in the solvents would result in some loss of CDI. It has been reported (8, (9) (10) (11) (12) (13) (14) (15) (16) and we confirmed that the yields of desired acylation products is often poor. Consequently, we studied the acy la ti on of the pep tide DNP-prolylserinamide by an acid imidazolide: the dinitro phenyl group allows detection (365 nm) of peptide-related pro ducts produced during the acylation; the acid chosen for this study was the diprotected derivative of trimesic acid (DT-TM acid) developed by us for derivatization of proteins (2 3), since it could readily be detected spectrally during hplc analysis, as well as being available to us in tritiated form. The products of the reaction of DT-TM imidazolide with DNP-prolylserinamide were analyzed by hplc as shown in Fig.  1 . The peptide is essentially pure and runs as a single peak at 4.0 min (panel A), the peak observed at 1. 2 min being due to solvent. Reaction of the peptide with acid activated with 1.5 equivalents of CDI resulted in complete loss of starting material and formation of two new products. The minor product ( 10%) eluting at 16.6 min (Fig. lB) was determined to be the desired trimesylated peptide since it contained the DNP chromophore and the tritiated form of the DT-TM acid; the major product (90%) eluting at 9. 1 min did not contain DT-TM acid (data not shown). A product eluting at the latter position is also generated when the peptide is incubated with CDI under acylation condi tions (Fig. l C) in the absence of DT-TM imidazolide. This product is presumed to be the imidazole-N-carboxylic ester of the peptide since the reaction between an alcohol and CDI to produce imidazole-N-carboxylic ester has been previously de scribed (22) and since it contains the peptide but not the DT-TM acid. Although the imidazolide is present in twice the concentra tion of the excess CDI, the trimesylated product is obtained only in about l 0% yield; this indicates that the CDI must react considerably faster than does the imidazolide under these condi tions. It was therefore concluded that this side reaction with CDI was responsible for the poor yields of the desired acylated peptide.
The effect of excess CDI on the rate of acylation was assessed quantitatively using this system and the results are shown in Fig.   2 . Acylation with DT-TM acid, that had been activated with 1.0 or 1.5 equivalents ofCDI resulted in 60 and 10% acylation of the peptide respectively. Addition of freshly activated reagent to these samples resulted in no increase in the amount of acylated peptide formed; this is consistent with the observed loss (Fig.  lB) of starting peptide under these conditions and the excess CDI thus had irreversibly blocked the hydroxyl group of the peptide.
The acylation reaction must therefore be performed in the absence of CDI. The obvious route of activation of the carbox ylic acid with only one equivalent of CDI still produced unsatis factory results since this required exact titration of the reagents and anhydrous conditions; in addition, as the CDI is consumed, the activation becomes slow, resulting in incomplete activation and the resulting presence of residual CDI. A better alternative would be the complete activation of the acid with an excess of CDI followed by removal of the unreacted CDI. This selective removal of CDI without significant loss of the activated acid should be possible since the reactivity of the CDI seemed to be much higher. This was confirmed by determining the reactivi ties of CDI and DT-TM imidazolide towards methanol in ben zene or DMF, as shown in Fig. 3 . The extent of reaction of CDI and DT-TM imidazolide under these conditions was determined by monitoring the absorbance at 290 nm (CDI) and at 310 nm (DT-TM imidazolide) at the specified times. The reactivities of the two reactive compounds towards methanol were similar in DMF while in benzene the rate of reaction of CDI was approx imately 175 times faster than that of the imidazolide. This higher reactivity of CDI in benzene should allow its selective reaction with hydroxyl groups without significant loss of the imidazo lide. The reaction of the excess CDI with the solid phase hy alent of residual CDI, in the absence of base; under these conditions no loss of radioactive DT-TM imidazolide was observed. The capacity of Sephadex LH-20 for CDI was deter mined to be 1.15 x 10-5 mol/mg as described in the ex perimental section.
The time course of acylation of the peptide after removal of the excess CDI using this procedure is shown in Fig. 2 . The reactions with DT-TM acid that had been activated with 1.0 or 1.5 equivalents CDI now both resulted in 100% reaction where as in the absence of the LH-20 treatment this reagent had produced yields of 60 and 10% respectively. Analysis of the final product of this reaction by hplc is shown in Fig. ID was absent. It is thus clear that the treatment with Sephadex LH-20 completely removes the CDI, resulting in faster acyla tion rates, more complete reactions, and purer products.
In those cases where availability of the acylating agent is limiting, a side reaction that may account for low yields is the formation of anhydride during activation, since the maximum yield via the anhydride based on acid is reduced to one half of that via the imidazolide. Th extent of anhydride formation during the preparation of the DT-TM imidazolide derivative was determined by hplc. This analysis involved an indirect assay in which DT-TM acid was activated as described in Table 1 , followed by the addition of 10 equivalents of cyclohexylamine.
Reaction of cyclohexylamine with DT-TM imidazolide formed the corresponding amide derivative, while reaction with DT TM anhydride resulted in the formation of one equivalent of the amide derivative and one equivalent of DT-TM acid. This reaction mixture was analyzed by hplc, as described in the legend to Table 1 , and monitored at 280 nm; the amount of free DT-TM acid generated afforded a quantitative assay of the amount of anhydride that had been formed.
The results in Table 1 clearly show that DMF is a relatively poor solvent for CDI activation of DT-TM acid, in all cases resulting in substantial formation of DT-TM anhydride. The presence of Et3N during the activation was found to double the amount of DT-TM anhydride formed. Apparently the genera tion of the DT-TM carboxylate ion results in the nucleophilic attack on the DT-TM imidazolide, thereby forming the anhy dride. Increasing the amount of CDI or the number of additions of DT-TM acid, in equal portions, was found to make little difference in reducing the anhydride formation. In the benzene/DMF mixture, the formation of DT-TM imidazolide was 100%, irrespective of the method of addition of the DT-TM acid (all at once or in four equal aliquots), and the activation reaction was found to be complete within 0.5 h. The activation of acids by CDI is thus best done in nonpolar solvents such as benzene in the absence of base, since more polar solvents or the presence of base result in anhydride formation. We have systematically assessed the imidazolide approach of carboxylic acid activation and have solved several problems associated with this procedure: activation of the acid is best achieved in a nonpolar solvent in the absence of any base. Complete formation of the imidazolide is ensured by an excess ofCDI with respect to the carboxylic acid. Any residual CDI can be entirely eliminated by a brief incubation with Sephadex LH-20 in dry benzene without any loss of the acid imidazolide.
The resulting imidazolide can be quantitatively converted to an ester or amide without any side reactions.
